SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-209745
Filing Date
2023-08-11
Accepted
2023-08-11 07:17:52
Documents
14
Period of Report
2023-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d337383d8k.htm   iXBRL 8-K 24546
2 EX-99.1 d337383dex991.htm EX-99.1 59704
6 GRAPHIC g337383capture.jpg GRAPHIC 15592
  Complete submission text file 0001193125-23-209745.txt   234091

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA acrv-20230811.xsd EX-101.SCH 2839
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE acrv-20230811_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acrv-20230811_pre.xml EX-101.PRE 11700
8 EXTRACTED XBRL INSTANCE DOCUMENT d337383d8k_htm.xml XML 3459
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 231161504
SIC: 2834 Pharmaceutical Preparations